This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into S1P1 modulators as treatment for Ulcerative Colitis with a focus on Zeposia (Ozanimod), Etrasimod, CBP-307 & VTX002

Ticker(s): BMY, PFE, CNTB, VTYX

Who's the expert?

Institution: University of Cincinnati

  • Adjunct Professor at University of Cincinnati.
  • Research focuses on the mechanisms of cellular damage and repair processes, including epithelial barrier function disruption, intestinal pathogens and commensals, and the use of animal models.
  • His work has resulted in the development of several new drugs and diagnostic tests for the treatment of a range of gastrointestinal/liver/nutrition conditions including identification of adhesion molecules (integrins)involved in inflammatory bowel diseases in human intestinal lymphocytes and early work in phase 1-2 trials of systemic antisense oligonucleotides in intestinal inflammation. ​

Interview Questions

Can you please detail your clinical experience and your current practice?

Added By: c_admin

Could you please walk us through the ulcerative colitis treatment landscape, specifically with the JAKs and the S1Ps, how often you're using them, the insurance steps required to use them, and how your patients are doing on either of those classes?

Added By: c_admin

What did you think about the general ozanimod data package?

Added By: c_admin

Is etrasimod going to have some better safety, or do you find this will just be almost like a "me too" agent to ozanimod?

Added By: c_admin

Is the S1P heart rate effect a big issue in clinical practice, or is it pretty much a non-issue as you do the monitoring?

Added By: c_admin

If an S1P could win a Crohn's disease trial, is that more valuable than a UC indication?

Added By: c_admin

Is there going to be a way to differentiate between the different S1Ps which are aprroved/being developed?

Added By: c_admin

There's a lot of mechanisms being pursued in UC. Is there any mechanism that's really exciting to you? Is there a possibility that the S1P class has basically leapfrogged that by the time it starts to get a little uptake, something newer in the market just snaps a lot of that first line use, whether it's an oral ENTYVIO or something similar?

Added By: c_admin

What's your general level of acceptance for the S1P class on a scale of one to 10?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.